Germany Neurology Clinical Trials Market Report 2022 to 2030

Germany Neurology Clinical Trials Market Analysis

$ 3999

The Germany Neurology Clinical Trials market is projected to grow from $191.4 Mn in 2022 to $256 Mn by 2030, registering a CAGR of 3.7% during the forecast period of 2022 - 2030. The market will be driven by the rising frequency of neurological illnesses such as Alzheimer's, Parkinson's, multiple sclerosis, and epilepsy and regulatory frameworks that encourage clinical trials. The market is segmented by phase, by study design & by indication. Some of the major players include Novartis, Pfizer & Bayer.

ID: IN10DECT005 CATEGORY: Clinical Trials GEOGRAPHY: Germany AUTHOR: Vidhi Upadhyay

Buy Now

Germany Neurology Clinical Trials Market Executive Summary

The Germany Neurology Clinical Trials market is projected to grow from $191.4 Mn in 2022 to $256 Mn by 2030, registering a CAGR of 3.7% during the forecast period of 2022 - 2030. Germany spends 12.8 % of its GDP on healthcare in 2021. For years, overall health spending as a proportion of GDP has grown. Germany has an extraordinary reputation for healthcare, combined with considerable governmental funding for the pharmaceutical business and a number of notable institutions that partner with the industry, such as Bayer-Schering Pharma with the University of Cologne. For ages, Germany has been a leader in pharmaceutical R&D.

In recent years, Germany has been a popular destination for clinical trials in neurology, particularly in the areas of neurodegenerative diseases such as Alzheimer's and Parkinson's. The country also has a strong focus on research related to multiple sclerosis, epilepsy, and stroke. In Germany, neurology clinical trials are normally carried out at specialist medical facilities and hospitals with well-established infrastructure and competent professionals.

Germany Neurology Clinical Trials Market

Market Dynamics

Market Growth Drivers

The German healthcare system is well-known for its excellent quality and accessibility, which makes it an appealing location for clinical trials. Also, the nation has a robust research and development (R&D) infrastructure, which is crucial for performing clinical trials. The rising frequency of neurological illnesses such as Alzheimer's, Parkinson's, multiple sclerosis, and epilepsy, among others, is one of the market's key drivers. Germany has a rapidly ageing population, which is likely to substantially raise the need for neurology clinical trials in the nation. Another important determinant is the availability of modern healthcare infrastructure, trained medical practitioners, and well-established regulatory frameworks that encourage clinical trials.

Market Restraints

There are various factors that may have an influence on the neurology clinical trials industry in Germany. The rising expense of clinical trials is one of the primary impediments. Conducting clinical trials is an expensive and time-consuming procedure, and many SMEs may struggle to acquire financing for their study. The regulatory cost associated with clinical trials is another constraint. The German regulatory environment is well-known for being stringent and complicated, which may be difficult for enterprises unfamiliar with the system. This might cause delays in securing regulatory permission for clinical studies, affecting the duration and expense of the research.

Competitive Landscape

Key Players

IQVIA
Novartis
Pfizer
Covance
Syneous Health
Icon Plc
GlaxoSmithKline
Biogen
Bayer (DEU)
Merck KGaA (DEU)
Boehringer Ingelheim (DEU)
Medpace – (DEU)

Notable Deals

In June 2022, Biogen invested more than $700 million in Alectos' preclinical oral Parkinson's medication to strengthen its pipeline.

July 2021, GlaxoSmithKline plc and Alector announced a strategic collaborative effort to develop and commercialise two clinical-stage, potential first-in-class monoclonal antibodies (AL001 and AL101) designed to elevate progranulin (PGRN) levels, that is linked to multiple neurodegenerative disorders, making it one of the most appealing genetically validated targets for the development of new immuno-neurology treatments.

Healthcare Policies and Regulatory Landscape & Reimbursement Scenario

In Germany, various regulatory authorities, including the Federal Institute for Drugs and Medical Devices (BfArM) and the Ethics Committee, are in charge of reviewing and authorizing clinical studies ensuring they are conducted in compliance with the German Medicines Act and the EU Clinical Trials Regulation. These regulatory authorities guarantee that clinical trials adhere to ethical and safety requirements, as well as that participants' rights and welfare are respected.

The German statutory health insurance system (GKV) is entrusted with covering the expenses of medical treatments, including those resulting from clinical trials, in terms of reimbursement. The GKV reimburses the expenses of therapies that have been shown in clinical studies to be effective and cost-efficient. The Federal Joint Committee (G-BA), an impartial organisation that analyses the benefits and costs of medical treatments, makes the decision to pay for treatment.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Clinical Trials Regulation in Country
1.6 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation

6. Methodology and Scope

Neurology Clinical Trials Market Segmentation

By Phase (Revenue, USD Billion):

Phase I
Phase II
Phase III
Phase IV

By Study Design Outlook (Revenue, USD Billion):

Epilepsy
Parkinson's Disease (PD)
Huntington's Disease
Stroke
Traumatic Brain Injury (TBI)
Amyotrophic Lateral Sclerosis (ALS)
Muscle regeneration
Others

By Indication Outlook (Revenue, USD Billion):

Interventional
Observational
Expanded Access

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.